Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (Nasdaq: COCP) appointed James Sapirstein as Chief Executive Officer, effective immediately, and plans to add him to the Board. The company is a clinical-stage biotech focused on novel antiviral therapeutics.
Sam Lee and Jim Martin step down as Co-CEOs; Lee becomes President and future Chief Scientific Officer, while Martin remains Chief Financial Officer. Sapirstein brings extensive antiviral development experience, participation in or leadership of 23 product launches, and a background as CEO or senior executive at several biopharma companies.
Cocrystal Pharma (Nasdaq: COCP) reported discovery-stage pan-viral replication inhibitors targeting hantavirus, bunyavirus and influenza. These direct-acting antivirals target a conserved region of the viral L-protein replication enzyme. In vitro data show potency with IC50 <50 nM against hantaan virus, related to Andes hantavirus. The company also highlighted its pan-viral protease inhibitor CDI-988, now in a Phase 1b norovirus challenge study, and plans to advance a pan-viral lead molecule to address viral diseases that currently lack approved antivirals or vaccines.
Cocrystal Pharma (Nasdaq: COCP) reported first quarter 2026 revenue of $225,000, all from an NIH SBIR award, versus no revenue in 2025. Net loss was $2.3 million ($0.17/share), similar to 2025. Unrestricted cash was $4.7 million with working capital of $3.7 million.
The company advanced CDI-988 for norovirus, completing enrollment in the first Phase 1b human challenge cohort and enrolling prevention/treatment cohorts, and obtained FDA Fast Track. It also progressed its influenza programs, including CC-42344 and an influenza A/B polymerase initiative supported by NIH funding.
Cocrystal Pharma (Nasdaq: COCP) presented klinical and preclinical data for CDI-988, a first oral direct-acting 3CL protease inhibitor for norovirus, at ICAR 2026. Key disclosures: Phase 1 safety data, ongoing Phase 1b human challenge study with stage 1 fully enrolled, and FDA Fast Track designation.
Phase 1 found CDI-988 generally safe to 1,200 mg; Phase 1b uses 1,200 mg twice daily for five days to assess prevention and treatment endpoints including symptom incidence and viral shedding.
Cocrystal Pharma (Nasdaq: COCP) announced that the U.S. FDA granted Fast Track designation to CDI-988, an oral direct-acting protease inhibitor being developed to prevent and treat norovirus infection. The designation enables earlier FDA interactions, rolling NDA review, and potential Priority Review.
CDI-988 targets a conserved 3CL protease region; a Phase 1b norovirus challenge study is currently underway at Emory University to evaluate both prevention and treatment.
Cocrystal Pharma (Nasdaq: COCP) reported 2025 results and pipeline updates on March 31, 2026. The company began a Phase 1b norovirus human challenge study at Emory for oral protease inhibitor CDI-988.
Key 2025 financials: R&D $5.1M (vs $12.5M), G&A $4.0M (vs $5.3M), net loss $8.8M ($0.78/share, vs $17.5M), cash $7.7M (vs $9.9M), working capital $5.9M, and 11.3M shares outstanding.
Cocrystal Pharma (Nasdaq: COCP) announced first subjects dosed in a Phase 1b randomized, double-blind, placebo-controlled human challenge study evaluating oral antiviral CDI-988 for prevention and treatment of norovirus. The study at Emory will enroll up to 40 healthy adults aged 18–49 infected with GII.2 (Snow Mountain Virus).
Primary endpoint: reduction in clinical symptom incidence versus placebo. Secondary endpoints: viral shedding, disease severity, safety, and pharmacokinetics. CDI-988 previously showed favorable Phase 1 safety; FDA issued a Study May Proceed letter in Sept 2025 and Emory IRB approved the study in Dec 2025. No approved norovirus treatments exist; norovirus causes an estimated $60 billion annual global economic burden.
Cocrystal Pharma (Nasdaq: COCP) will present initial Phase 1 and ongoing Phase 1b norovirus challenge study data for CDI-988 at ICAR2026, April 27–May 1 in Prague.
CDI-988 is described as the company’s first oral, direct-acting protease inhibitor developed for prevention and treatment of acute norovirus gastroenteritis and as a pan-viral 3CL protease inhibitor.
Cocrystal Pharma (Nasdaq: COCP) received Institutional Review Board approval from Emory University School of Medicine to start a Phase 1b human challenge study of CDI-988 for prevention and treatment of norovirus.
Key facts: the study follows FDA IND clearance and a Study May Proceed letter, will enroll up to 40 healthy adults (ages 18-49), use norovirus GII.2 challenge, and expects subject enrollment in Q1 2026. Primary endpoint is reduction in clinical symptoms; secondary endpoints include viral shedding and disease severity.
Cocrystal Pharma (Nasdaq: COCP) will present at Noble Capital Markets’ 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 AM ET. James Martin, CFO and co-CEO, will give a company overview and a clinical progress update at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
A video webcast of the presentation will be posted on December 4, 2025 on the company website and will be archived for 90 days. Interested investors can attend the conference at a discounted rate using code COCPNOBLECON.